source
- Adicet Bio's off-the-shelf CAR-T therapy shows lupus remission in early Phase 1 trialAdicet Bio reported that its off-the-shelf CAR-T product prula-cel induced remission in more than half of lupus patients enrolled in a small Phase 1 study. One year after a single infusion, 12 of…
- Novo’s stock tumbles after two-year GLP-1 boom as AI drug-discovery startups land huge funding roundsNovo’s shares, which peaked above $140 in June 2024 during a surge in demand for its GLP-1 drugs Ozempic and Wegovy, have fallen sharply over the past two years. The decline reflects a broader mark…